Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Norepinephrine Transporter as a Target for Imaging and Therapy.

Pandit-Taskar N, Modak S.

J Nucl Med. 2017 Sep;58(Suppl 2):39S-53S. doi: 10.2967/jnumed.116.186833. Review.

2.

Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.

Pandit-Taskar N, Zanzonico P, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S.

Clin Nucl Med. 2017 Oct;42(10):741-748. doi: 10.1097/RLU.0000000000001752.

PMID:
28759518
3.

Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide.

Edmondson DA, Karski EE, Kohlgruber A, Koneru H, Matthay KK, Allen S, Hartmann CL, Peterson LE, DuBois SG, Coleman MA.

Radiat Res. 2016 Sep;186(3):235-44. doi: 10.1667/RR14263.1. Epub 2016 Aug 24.

4.

Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

George SL, Falzone N, Chittenden S, Kirk SJ, Lancaster D, Vaidya SJ, Mandeville H, Saran F, Pearson AD, Du Y, Meller ST, Denis-Bacelar AM, Flux GD.

Nucl Med Commun. 2016 May;37(5):466-72. doi: 10.1097/MNM.0000000000000470.

5.

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.

Bushnell DL, Madsen MT, O'cdorisio T, Menda Y, Muzahir S, Ryan R, O'dorisio MS.

EJNMMI Res. 2014 Dec;4(1):38. doi: 10.1186/s13550-014-0038-2. Epub 2014 Sep 10.

6.

Clinical and pathological staging of the cancer at the nanoscale.

Moawad EY.

Cancer Nanotechnol. 2012;3(1-6):37-46. Epub 2012 Jul 22.

7.

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK.

Clin Cancer Res. 2015 Jun 15;21(12):2715-21. doi: 10.1158/1078-0432.CCR-14-3240. Epub 2015 Feb 18.

8.

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.

DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, Courtier J, Mosse YP, Matthay KK.

Br J Cancer. 2015 Feb 17;112(4):644-9. doi: 10.1038/bjc.2015.12. Epub 2015 Jan 20.

9.

Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.

Streby KA, Shah N, Ranalli MA, Kunkler A, Cripe TP.

Pediatr Blood Cancer. 2015 Jan;62(1):5-11. doi: 10.1002/pbc.25200. Epub 2014 Aug 30. Review.

10.

Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.

Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK, Seo Y.

Mol Imaging Biol. 2015 Apr;17(2):284-94. doi: 10.1007/s11307-014-0783-7.

11.

Promising therapeutic targets in neuroblastoma.

Matthay KK, George RE, Yu AL.

Clin Cancer Res. 2012 May 15;18(10):2740-53. doi: 10.1158/1078-0432.CCR-11-1939. Review.

12.

Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.

Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK.

Mol Imaging Biol. 2012 Dec;14(6):735-42. doi: 10.1007/s11307-012-0552-4.

13.

Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.

Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK.

Cancer. 2011 Sep 15;117(18):4286-93. doi: 10.1002/cncr.25987. Epub 2011 Mar 8.

14.

Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.

Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y.

Med Phys. 2010 Sep;37(9):4861-7.

15.

Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.

Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK.

Pediatr Blood Cancer. 2011 Feb;56(2):191-201. doi: 10.1002/pbc.22767. Epub 2010 Sep 9.

16.

The effect of volume-of-interest misregistration on quantitative planar activity and dose estimation.

Song N, He B, Frey EC.

Phys Med Biol. 2010 Sep 21;55(18):5483-97. doi: 10.1088/0031-9155/55/18/014. Epub 2010 Aug 27.

17.

131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.

Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, Koral KF, Kaminski MS, Avram AM.

J Nucl Med. 2010 Jul;51(7):1155-62. doi: 10.2967/jnumed.110.075176. Epub 2010 Jun 16.

19.

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.

Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P.

J Clin Oncol. 2009 Sep 1;27(25):4162-8. doi: 10.1200/JCO.2008.21.3496. Epub 2009 Jul 27.

Supplemental Content

Support Center